This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is/are a genetic/environmental component(s) to developing blood cancer.
Description
OUTLINE: This is an observational study.
Patients undergo blood sample collection and complete surveys on study. Patients' medical records are also reviewed.
Who can participate
Inclusion Criteria:
* Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
* Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
OR
* Subjects who have or have had a solid tumor diagnosis and any of the following:
* At least 4 months of exposure to a PARP inhibitor
* Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm
Exclusion Criteria:
* Individuals with a life expectancy of less than 6 months
Interventions
Non-Interventional Study
OTHER
Locations
1
United States (1)
Fred Hutch/University of Washington Cancer Consortium
БГ